Cytori Therapeutics Inc (CYTX) : Analyst Rating Update

Cytori Therapeutics Inc (CYTX) : 2 analysts are covering Cytori Therapeutics Inc (CYTX) and their average rating on the stock is 1, which is read as a Strong Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels.

Cytori Therapeutics Inc (CYTX) : Currently there are 2 street experts covering Cytori Therapeutics Inc (CYTX) stock. The most bullish and bearish price target for the stock is $11 and $5 respectively for the short term. The average price target of all the analysts comes to $8. The estimated standard deviation from the target is $4.24.

Cytori Therapeutics Inc (NASDAQ:CYTX): The stock opened at $2.03 on Wednesday but the bulls could not build on the opening and the stock topped out at $2.03 for the day. The stock traded down to $1.97 during the day, due to lack of any buying support eventually closed down at $2.01 with a loss of -1.47% for the day. The stock had closed at $2.04 on the previous day. The total traded volume was 162,525 shares.

The company shares have dropped -71.67% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $8.25 and the one year low was seen on Jun 24, 2016. The 50-Day Moving Average price is $2.42 and the 200 Day Moving Average price is recorded at $2.92.

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury. The Company commercializes the Celution System under select medical device approvals, clearances and registrations to research customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan and other regions. The Company offers ECCO-50, a cure for knee osteoarthritis, which is in ECCO-50 Phase IIA/B of development. It offers ECCI-50, a cure for urinary incontinence, which is in Phase II/III of development. The Company is also developing DCCT-10, a cure for cutaneous thermal injury.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.